- Home
- CBIO vs OLMA Comparison
CBIO vs OLMA Comparison
Compare CBIO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- OLMA
- Stock Information
- Founded
- CBIO 2003
- OLMA 2006
- Country
- CBIO United States
- OLMA United States
- Employees
- CBIO N/A
- OLMA N/A
- Industry
- CBIO
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- CBIO
- OLMA Health Care
- Exchange
- CBIO Nasdaq
- OLMA Nasdaq
- Market Cap
- CBIO 308.0M
- OLMA 378.9M
- IPO Year
- CBIO N/A
- OLMA 2020
- Fundamental
- Price
- CBIO $14.29
- OLMA $5.46
- Analyst Decision
- CBIO Strong Buy
- OLMA Strong Buy
- Analyst Count
- CBIO 5
- OLMA 5
- Target Price
- CBIO $25.60
- OLMA $24.00
- AVG Volume (30 Days)
- CBIO 98.3K
- OLMA 450.7K
- Earning Date
- CBIO 07-31-2025
- OLMA 08-11-2025
- Dividend Yield
- CBIO N/A
- OLMA N/A
- EPS Growth
- CBIO N/A
- OLMA N/A
- EPS
- CBIO N/A
- OLMA N/A
- Revenue
- CBIO N/A
- OLMA N/A
- Revenue This Year
- CBIO N/A
- OLMA N/A
- Revenue Next Year
- CBIO N/A
- OLMA N/A
- P/E Ratio
- CBIO N/A
- OLMA N/A
- Revenue Growth
- CBIO N/A
- OLMA N/A
- 52 Week Low
- CBIO $10.83
- OLMA $2.86
- 52 Week High
- CBIO $21.40
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- OLMA 54.42
- Support Level
- CBIO $13.50
- OLMA $5.54
- Resistance Level
- CBIO $16.00
- OLMA $5.85
- Average True Range (ATR)
- CBIO 0.79
- OLMA 0.30
- MACD
- CBIO 0.16
- OLMA -0.01
- Stochastic Oscillator
- CBIO 39.68
- OLMA 51.79
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.